SEC Filing Summary: 180 Life Sciences Corp.
Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (formerly KBL Merger Corp. IV) on August 6, 2021. The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Palo Alto, California. The company trades on The NASDAQ Stock Market LLC under the symbols ATNF (Common Stock) and ATNFW (Warrants).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance amendments and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the formal amendment and restatement of the Company's Bylaws to reflect a name change. As previously disclosed in a November 2020 Form 8-K, the Company changed its name from KBL Merger Corp. IV to 180 Life Sciences Corp. following a business combination. On August 6, 2021, the Board of Directors approved the updated Bylaws to codify this change.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural update of the Bylaws.
Key Facts for Investor Verification
- The Company's name change from KBL Merger Corp. IV to 180 Life Sciences Corp. was finalized via Bylaw amendment on August 6, 2021.
- The Amended and Restated Bylaws are filed as Exhibit 3.1 to this report.
- The Company is classified as an emerging growth company.
- No financial performance data is included in this specific filing.